The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
German Primate Center · University of Göttingen · +4 more institutions
Abstract
Abstract The emergence of a novel, highly pathogenic coronavirus, 2019-nCoV, in China, and its rapid national and international spread pose a global health emergency. Coronaviruses use their spike proteins to select and enter target cells and insights into nCoV-2019 spike (S)-driven entry might facilitate assessment of pandemic potential and reveal therapeutic targets. Here, we demonstrate that 2019-nCoV-S uses the SARS-coronavirus receptor, ACE2, for entry and the cellular protease TMPRSS2 for 2019-nCoV-S priming. A TMPRSS2 inhibitor blocked entry and might constitute a treatment option. Finally, we show that the serum form a convalescent SARS patient neutralized 2019-nCoV-S-driven entry. Our results reveal…
Citation impact
- FWCI
- —
- Percentile
- —
- References
- 38
Authors
6- MHMarkus HoffmannCorresponding
German Primate Center
- HKHannah Kleine‐Weber
German Primate Center, University of Göttingen
- NKNadine Krüger
University of Veterinary Medicine Hannover, Foundation
- MAMarcel A. Müller
Sechenov University, German Center for Infection Research, Charité - Universitätsmedizin Berlin
- CDChristian Drosten
Sechenov University, German Center for Infection Research, Charité - Universitätsmedizin Berlin
Topics & keywords
- Coronavirus
- TMPRSS2
- Virology
- Pandemic
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- Coronavirus disease 2019 (COVID-19)
- Severe acute respiratory syndrome coronavirus
- Betacoronavirus
- Good health and well-being